Chimeric antigen receptor‐T cell therapy shows similar efficacy and toxicity in patients with diffuse large B‐cell lymphoma aged 70 and older compared to younger patients: A multicenter cohort study

Chimeric antigen receptor‐T cell therapy shows similar efficacy and toxicity in patients with diffuse large B‐cell lymphoma aged 70 and older compared to younger patients: A multicenter cohort study

Abstract CD19‐directed chimeric antigen receptor (CAR)‐T cell therapy has become a standard treatment for relapsed/refractory diffuse large B‐cell lymphoma (r/r DLBCL). While the benefits of CAR‐T cell treatment are clear in the general patient population, there remains a relative scarcity of real‐w...

Full description

Bibliographic Details
Main Authors: Philipp Berning, Evgenii Shumilov, Markus Maulhardt, Hristo Boyadzhiev, Andrea Kerkhoff, Simon Call, Christian Reicherts, Anna O. Saidy, Enver Aydilek, Michèle Hoffmann, Urban Novak, Michael Daskalakis, Norbert Schmitz, Matthias Stelljes, Gerald Wulf, Ulrike Bacher, Georg Lenz, Thomas Pabst
Format: Article
Language:English
Published: Wiley 2024-03-01
Series:HemaSphere
Online Access:https://doi.org/10.1002/hem3.54

Internet

https://doi.org/10.1002/hem3.54

Similar Items